<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00495729</url>
  </required_header>
  <id_info>
    <org_study_id>OXS104092</org_study_id>
    <nct_id>NCT00495729</nct_id>
  </id_info>
  <brief_title>15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects.</brief_title>
  <official_title>A Single-blind, Randomised, Placebo-controlled, 15 Day Repeated-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SB-649868 and Its Interaction With the CYP3A4 Isoenzyme in Healthy Male Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects will be screened within 28 days, Simvastatin dose and single SB-649868 dose 10 and 7
      days prior to repeat dosing respectively, 15 days SB-649868 repeat dosing with safety and
      cognition function tests.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 18, 2007</start_date>
  <completion_date type="Actual">August 4, 2007</completion_date>
  <primary_completion_date type="Actual">August 4, 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>-AE, Lab values and cardiovascular monitoring after the SD and 14 days RD period (15 days)</measure>
    <time_frame>after the SD and 14 days RD period (15 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>- SB649868 levels on days -7, 1, 4, 7 and 14 (pre-dose and post-dose)</measure>
    <time_frame>on days -7, 1, 4, 7 and 14 (pre-dose and post-dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>- Simvastatine and Beta-idroxy-simvastatine levels on days -10,1,4,7 and 15</measure>
    <time_frame>on days -10,1,4,7 and 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cognitive functions, sleep profile and appetite assessment on days -7, 7 and 14.</measure>
    <time_frame>on days -7, 7 and 14.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Sleep Initiation and Maintenance Disorders</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Cohort 1 will be randomized to receive 5 milligram (mg) of SB-649868 or Placebo along with 10 mg of simvastatin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Cohort 2 will be randomized to receive two or three times higher than the starting dose of SB-649868 or Placebo along with 10 mg of simvastatin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in Cohort 3 will be randomized to dose higher than that administered in Cohort 2 of SB-649868 or Placebo along with 10 mg of simvastatin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-649868</intervention_name>
    <description>Subjects will receive SB-649868 5 mg, 25 mg tablets orally 1 hour prior to simvastatin administration.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive matching placebo tablets to SB-649868 orally 1 hour prior to simvastatin administration.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Subjects will receive Simvastatin 10 mg tablets orally.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult male subjects aged between 18 and 65 years of age inclusive.

          -  Body weight =50 kg and BMI within the range 18.5-29.9 kg/m2 inclusive.

          -  Healthy as judged by responsible physician. No clinically significant abnormality
             identified on the medical or laboratory evaluation and 12-lead ECG. A subject with a
             clinical abnormality or laboratory parameters outside the reference range for this age
             group may be included only if the Investigator and the Medical Monitor considers that
             the finding will not introduce additional risk factors and will not interfere with the
             study procedures.

          -  Subjects will have blood pressure measurements within the normal range for healthy
             volunteers.

        Exclusion Criteria:

          -  The subject has a positive pre-study urine drug/ alcohol urine screen.

          -  A positive pre-study Hepatitis B surface antigen, Hepatitis C antibody, or HIV 1/2
             result at the screening visit.

          -  Abuse of alcohol defined as an average weekly intake of greater than 21 units or an
             average daily intake of greater than 3 units.

          -  Subject complains of sleep disturbances and/ or is receiving treatment for sleep
             disorders.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/OXS104092?search=study&amp;search_terms=OXS104092#rs</url>
    <description>Results for study OXS104092 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2007</study_first_submitted>
  <study_first_submitted_qc>June 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2007</study_first_posted>
  <last_update_submitted>August 5, 2017</last_update_submitted>
  <last_update_submitted_qc>August 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SB-649868,</keyword>
  <keyword>Simvastatin</keyword>
  <keyword>Repeated dose,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

